1 Department of Endocrinology, Diabetes and Nutrition, Hôpital Haut Lévêque, CHU and University of Bordeaux, Pessac, France
| 2 Fédération d’Endocrinologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France
| 3 Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital and University of Lille, Lille, France
| 4 Department of Endocrinology, Diabetes and Nutrition, Médipole Lyon Villeurbanne, Villeurbanne, France
| 5 University Grenoble Alpes, Service d’Endocrinologie CHU Grenoble Alpes, Unité Mixte de Recherche INSERM-CEA-UGA UMR1036, Grenoble Alpes, France
| 6 Department of Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre and University Paris-Saclay, Paris, France
FassnachtM, DekkersOM, ElseT, BaudinE, BerrutiA, de KrijgerR, HaakHR, MihaiR, AssieG, TerzoloM. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors. European Journal of Endocrinology2018179G1–G46. (https://doi.org/10.1530/EJE-18-0608)
FassnachtMDekkersOMElseTBaudinEBerrutiAde KrijgerRHaakHRMihaiRAssieGTerzoloM. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors. European Journal of Endocrinology2018179G1–G46. (https://doi.org/10.1530/EJE-18-0608))| false
PuglisiS, PerottiP, PiaA, ReimondoG, TerzoloM. Adrenocortical carcinoma with hypercortisolism. Endocrinology and Metabolism Clinics of North America201847395–407. (https://doi.org/10.1016/j.ecl.2018.02.003)
PuglisiSPerottiPPiaAReimondoGTerzoloM. Adrenocortical carcinoma with hypercortisolism. Endocrinology and Metabolism Clinics of North America201847395–407. (https://doi.org/10.1016/j.ecl.2018.02.003))| false
CorcuffJB, YoungJ, Masquefa-GiraudP, ChansonP, BaudinE, TabarinA. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology2015172473–481. (https://doi.org/10.1530/EJE-14-0913)
CorcuffJBYoungJMasquefa-GiraudPChansonPBaudinETabarinA. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology2015172473–481. (https://doi.org/10.1530/EJE-14-0913))| false
PivonelloR, FleseriuM, Newell-PriceJ, BertagnaX, FindlingJ, ShimatsuA, GuF, AuchusR, LeelawattanaR & LeeEJ et al.Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet: Diabetes and Endocrinology20208748–761. (https://doi.org/10.1016/S2213-8587(2030240-0)
PivonelloRFleseriuMNewell-PriceJBertagnaXFindlingJShimatsuAGuFAuchusRLeelawattanaRLeeEJEfficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet: Diabetes and Endocrinology20208748–761. (https://doi.org/10.1016/S2213-8587(2030240-0))| false
HaissaguerreM, PuertoM, NunesML, TabarinA. Efficacy and tolerance of osilodrostat in patients with severe Cushing’s syndrome due to non-pituitary cancers. European Journal of Endocrinology2020183L7–L9. (https://doi.org/10.1530/EJE-20-0557)
HaissaguerreMPuertoMNunesMLTabarinA. Efficacy and tolerance of osilodrostat in patients with severe Cushing’s syndrome due to non-pituitary cancers. European Journal of Endocrinology2020183L7–L9. (https://doi.org/10.1530/EJE-20-0557))| false
BaudryC, CosteJ, Bou KhalilR, SilveraS, GuignatL, GuibourdencheJ, AbbasH, LegmannP, BertagnaX, BertheratJ. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. European Journal of Endocrinology2012167473–481. (https://doi.org/10.1530/EJE-12-0358)
BaudryCCosteJBou KhalilRSilveraSGuignatLGuibourdencheJAbbasHLegmannPBertagnaXBertheratJ. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. European Journal of Endocrinology2012167473–481. (https://doi.org/10.1530/EJE-12-0358))| false
BessieneL, BonnetF, TenenbaumF, JozwiakM, CorchiaA, BertheratJ, GroussinL. Rapid control of severe ectopic Cushing’s syndrome by oral osilodrostat monotherapy. European Journal of Endocrinology2021184L13–L15. (https://doi.org/10.1530/EJE-21-0147)
BessieneLBonnetFTenenbaumFJozwiakMCorchiaABertheratJGroussinL. Rapid control of severe ectopic Cushing’s syndrome by oral osilodrostat monotherapy. European Journal of Endocrinology2021184L13–L15. (https://doi.org/10.1530/EJE-21-0147))| false